Targacept Inc. and AstraZeneca have enrolled the first patient in a Phase III program for depression drug candidate TC-5214, which showed positive results in Phase II testing as an add-on therapy for patients who did not respond well to prior treatment with another antidepressant, citalopram. (BioWorld Today)

Shares in Repros Therapeutics Inc. spiked Friday on news that the FDA had cleared the company to perform a new study of Proellex, lifting a long-standing clinical hold that had been placed on its drug candidate for uterine fibroids and endometriosis. (BioWorld Today)